FDA-approved medications for dementia are unlike non-pharmacological interventions as they are counterproductive

References

• Aldy, J. E., and W. K. Viscusi. 2008. “Adjusting the Value of a Statistical Life for Age and Cohort Effects.” The Review of Economics and Statistics 90 (3): 573–581. doi:10.1162/rest.90.3.573.
   Web of Science ®Google Scholar
• Alzheimer’s Association. 2021. “2021 Alzheimer’s Disease Facts and Figures.” Alzheimer’s Dementia 17 (3): 1–108.
   Web of Science ®Google Scholar
• Austin, P. C. 2011. “An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.” Multivariate Behavioral Research 46 (3): 399–424. doi:10.1080/00273171.2011.568786.
   PubMed Web of Science ®Google Scholar
• Beekly, D. L., E. R. Ramos, W. W. Lee, et al. 2007. “The National Alzheimer’s Coordinating Center (NACC) Database: The Uniform Data Set.” Alzheimer Disease and Associated Disorders 21 (3): 249–258. doi:10.1097/WAD.0b013e318142774e.
   PubMed Web of Science ®Google Scholar
• Brent, R. J. 2018a. “Estimating the Monetary Benefits of Medicare Eligibility for Reducing Symptoms of Dementia.” Applied Economics 50 (58): 6327–6340. doi:10.1080/00036846.2018.1489519.
   PubMed Web of Science ®Google Scholar
• Brent, R. J. 2018b. “The Value of a Year’s General Education for Reducing the Symptoms of Dementia.” Applied Economics 50 (25): 2812–282. doi:10.1080/00036846.2017.1409420
   PubMed Web of Science ®Google Scholar
• Brent, R. J. 2019. “A CBA of Hearing Aids, Including the Benefits of Reducing the Symptoms of Dementia.” Applied Economics 51 (28): 3091–3103. doi:10.1080/00036846.2018.1564123.
   PubMed Web of Science ®Google Scholar
• Brent, R. J. 2020. “A CBA of Corrective Lenses, Including the Benefits for Reducing the Symptoms of Dementia.” Applied Economics 52 (48): 5218–5229. doi:10.1080/00036846.2020.1761533.
   Web of Science ®Google Scholar
• Brent, R. J. 2021. “Misconceptions Regarding Dementia: What It Is, What Can Be Done and What Should Be Done.” International Journal of Psychology and Behavior Analysis 7: 181.
   Google Scholar
• Brent, R. J. 2022a. Cost-Benefit Analysis and Dementia: New Interventions. Cheltenham, UK: Edward Elgar.
   Google Scholar
• Brent, R. J. 2022b. “The Benefits of Not Living in Nursing Homes.” Applied Economics 54 (32): 3740–3750. doi:10.1080/00036846.2021.1983141.
   Web of Science ®Google Scholar
• Brent, R. J. 2022c. “Life Expectancy in Nursing Homes.” Applied Economics 54 (16): 1877–1888. doi:10.1080/00036846.2021.1983138.
   Web of Science ®Google Scholar
• Hausman, J. A. 1978. “Specification Tests in Econometrics.” Econometrica 46 (6): 1251–1371. doi:10.2307/1913827.
   Web of Science ®Google Scholar
• Morris, J. C. 1997. “Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type.” International Psychogeriatrics 9 (Suppl.1): 173–176. doi:10.1017/S1041610297004870.
   PubMedGoogle Scholar
• Morris, J. C., S. Weintraub, H. C. Chui, J. Cummings, C. DeCarli, S. Ferris, N. L. Foster, et al. 2006. “The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data from Alzheimer Disease Centers.” Alzheimer Disease and Associative Disorders 20 (4): 210–216. doi:10.1097/01.wad.0000213865.09806.92.
   PubMed Web of Science ®Google Scholar
• Murray, M. P. 2006. Econometrics: A Modern Introduction. Boston: Addison Wesley.
   Google Scholar
• Thibault, C.S. -T., I. O. Stillman, S. Chen, D. Getsios, I. Proskorovsky, L. Herrnandez, and S. Dixit. 2015. “Cost-Utility Analysis of Memantine Extended Release Added to Cholinesterase Inhibitors Compared to Cholinesterase Inhibitor Monotherapy for the Treatment of Moderate-To-Severe Dementia of the Alzheimer’s Type in the US.” Journal of Medical Economics 18 (11): 930–943. doi:10.3111/13696998.2015.1063501.
   PubMed Web of Science ®Google Scholar
• Vaisey, S., and A. Miles. 2017. “What You Can—and Can’t—do with Three-Wave Panel Data.” Sociological Methods & Research 4 (1): 44–67. doi:10.1177/0049124114547769.
   Web of Science ®Google Scholar
• Weintraub, S., D. Salmon, N. Mercaldo, S. Ferris, N. R. Graff-Radford, H. Chui, J. Cummings, et al. 2009. “The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): The Neuropsychological Test Battery.” Alzheimer Disease and Associative Disorders 23 (2): 91. doi:10.1097/WAD.0b013e318191c7dd.
   PubMed Web of Science ®Google Scholar
• Wooldridge, J. W. 2002. Econometric Analysis of Cross-Section and Panel Data. Cambridge: MIT Press.
   Google Scholar
• Yanusa, I., S. Alsahali, A. Rane, and T. Eguale. 2021. “Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-To-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis.” Journal of Alzheimer’s Disease Reports 5 (1): 705–713. doi:10.3233/ADR-210307.
   PubMedGoogle Scholar